Beta Bionics Projects 2026 Revenue Between $124M and $126M Following FDA Clearance for Mint Patch Pump
Beta Bionics (BBNX) has provided financial guidance projecting revenue in the range of $124 million to $126 million for the fiscal year 2026. This outlook follows a significant regulatory milestone achieved in September, where the company received FDA clearance for its Mint patch pump technology. The company plans to begin full commercialization of the Mint device in the United States during the first quarter of 2027. CEO Sean Saint highlighted the transformative potential of the product as the company prepares for this upcoming market entry.
Tickers: $BBNX
Topics: FDA Clearance Medical Devices Product Commercialization
Read the full article at Seeking Alpha
Part of the story Beta Bionics, Inc. - 10-Q Filing (4 articles)